본문 바로가기
KERD
논문KCI 등재

뇌졸중 일차예방을 위한 최신 과학적 근거(2011): 이상지질혈증과 염증

2011 Update of Scientific Statement for the Primary Prevention of Stroke: Dyslipidemia and Inflammation

조용진|박종무|배희준|이병철|유경호|윤병우|나정호|정진상|강규식|홍근식|허지회|한상원|권순억|구자성|오창완|김한영
대한신경과학회 (Korean Neurological Association)|2012.08|대한신경과학회지 (Journal of the Korean Neurological Association)|제30권 제3호|pp. 159-169|DOI http://dx.doi.org/

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

StrokeInflammationPrimary preventionDyslipidemiaScientific statement
주제분류신경과학

초록

Background: This scientific statement is intended to provide a systematic review of new evidences in dyslipidemia and inflammation for primary stroke prevention. Methods: Using a structured literature search, we identified major observational studies, clinical trials, meta-analyses,and updated major guidelines published between July 2007 and November 2010. In addition to the brief summary of earlier evidences employed in the first edition of Korean clinical practice guideline for primary prevention of stroke, we summarized the newly identified evidences. Results: For dyslipidemia, observational studies further support a strong association between ischemic stroke and high total and low-density lipoprotein cholesterol and low high-density lipoprotein cholesterol. Two clinical trials and 6meta-analyses confirm statin efficacy for primary prevention of stroke in high risk patients. Efficacy of other lipid-lowering agents is not established. For inflammation, inflammatory markers might help to identify patients having high risk for stroke or cardiovascular event and to decide whether statin therapy is indicated, but its usefulness for broad population needs to be confirmed. Conclusions: Writing committee will continue to keep an eye on upcoming evidences to timely update the guideline for primary stroke prevention in dyslipidemia and inflammation.

Abstract

Background: This scientific statement is intended to provide a systematic review of new evidences in dyslipidemia and inflammation for primary stroke prevention. Methods: Using a structured literature search, we identified major observational studies, clinical trials, meta-analyses,and updated major guidelines published between July 2007 and November 2010. In addition to the brief summary of earlier evidences employed in the first edition of Korean clinical practice guideline for primary prevention of stroke, we summarized the newly identified evidences. Results: For dyslipidemia, observational studies further support a strong association between ischemic stroke and high total and low-density lipoprotein cholesterol and low high-density lipoprotein cholesterol. Two clinical trials and 6meta-analyses confirm statin efficacy for primary prevention of stroke in high risk patients. Efficacy of other lipid-lowering agents is not established. For inflammation, inflammatory markers might help to identify patients having high risk for stroke or cardiovascular event and to decide whether statin therapy is indicated, but its usefulness for broad population needs to be confirmed. Conclusions: Writing committee will continue to keep an eye on upcoming evidences to timely update the guideline for primary stroke prevention in dyslipidemia and inflammation.

참고문헌 (56)

  1. Korean Center for Disease Control., "Construction of National Surveillance System for Cardiovascular & Cerebrovascular Diseases", Korean Center for Disease Control, ~ (2006)
  2. O'Donnell MJ, "Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study", Lancet, 376, pp.112~123 (2010)
  3. Clinical Research Center for Stroke, "Clinical Practice Guideline for Stroke" (2009), Clinical Research Center for Stroke
  4. Goldstein LB, "Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2011, pp.42, 517~584
  5. "Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration", Lancet, 346, pp.1647~1653 (1995)
  6. Iso H, "Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial", N Engl J Med, 320, pp.904~910 (1989)
  7. Kagan A, "Factors related to stroke incidence in Hawaii Japanese men. The Honolulu Heart Study", Stroke, 11, pp.14~21 (1980)
  8. Ueshima H, "Multivariate analysis of risk factors for stroke. Eight-year follow-up study of farming villages in Akita, Japan", Prev Med, 9, pp.722~740 (1980)
  9. Bots ML, "Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe", J Epidemiol Community Health, 56(Suppl 1), pp.19~24 (2002)
  10. Shahar E, "Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study", Stroke, 34, pp.623~631 (2003)
  11. Leppala JM, "Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants", Stroke, 30, pp.2535~2540 (1999)
  12. Horenstein RB, "Cholesterol predicts stroke mortality in the Women's Pooling Project", Stroke, 33, pp.1863~1868 (2002)
  13. Zhang X, "Cholesterol, coronary heart disease, and stroke in the Asia Pacific region", Int J Epidemiol, 32, pp.563~572 (2003)
  14. Kurth T, "Lipid levels and the risk of ischemic stroke in women", Neurology, 68, pp.556~562 (2007)
  15. Gordon T, "Lipoproteins, cardiovascular disease, and death. The Framingham study", Arch Intern Med, 141, pp.1128~1131 (1981)
  16. Koren-Morag N, "Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry", Arch Intern Med, 162, pp.993~999 (2002)
  17. Soyama Y, "High-density lipoprotein cholesterol and risk of stroke in Japanese men and women: the Oyabe Study", Stroke, 34, pp.863~868 (2003)
  18. Wannamethee SG, "HDL-Cholesterol, total cholesterol, and the risk of stroke in middle-aged British men", Stroke, 31, pp.1882~1888 (2000)
  19. Lindenstrom E, "Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study", BMJ, 309, pp.11~15 (1994)
  20. Psaty BM, "The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study", J Am Geriatr Soc, 52, pp.1639~1647 (2004)
  21. Amarenco P, "Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis", Stroke, 35, pp.2902~2909 (2004)
  22. Baigent C, "Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins", Lancet, 366, pp.1267~1278 (2005)
  23. LaRosa JC, "Intensive lipid lowering with atorvastatin in patients with stable coronary disease", N Engl J Med, 352, pp.1425~1435 (2005)
  24. Goldberg RB, "Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial", Circulation, 98, pp.2513~2519 (1998)
  25. Sever PS, "Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial", Lancet, 361, pp.1149~1158 (2003)
  26. Collins R, "Peto R; Heart Protection Study Collaborative Group. MRC", BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo- controlled trial, 2003, pp.361, 2005~2016
  27. Colhoun HM, "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial", Lancet, 364, pp.685~696 (2004)
  28. "Clofibrate and niacin in coronary heart disease", JAMA, 231, pp.360~381 (1975)
  29. Bloomfield Rubins H, "Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT)", Circulation, 103, pp.2828~2833 (2001)
  30. Sanossian N, "High-density lipoprotein cholesterol: an emerging target for stroke treatment", Stroke, 38, pp.1104~1109 (2007)
  31. Amarenco P, "High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review", Atherosclerosis, 196, pp.489~496 (2008)
  32. Freiberg JJ, "Nonfasting triglycerides and risk of ischemic stroke in the general population", JAMA, 300, pp.2142~2152 (2008)
  33. Bansal S, "Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women", JAMA, 298, pp.309~316 (2007)
  34. Smolders B, "Lipoprotein (a) and stroke: a meta-analysis of observational studies", Stroke, 38, pp.1959~1966 (2007)
  35. Ridker PM, "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein", N Engl J Med, 359, pp.2195~2207 (2008)
  36. de Lorgeril M, "Cholesterol lowering, cardiovascular diseases, and the rosuvastatin- JUPITER controversy: a critical reappraisal", Arch Intern Med, 170, pp.1032~1036 (2010)
  37. Amarenco P, "Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention", Lancet Neurol, 8, pp.453~463 (2009)
  38. Baigent C, "Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials", Lancet, 376, pp.1670~1681 (2010)
  39. Mora S, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials", Circulation, 121, pp.1069~1077 (2010)
  40. Bruckert E, "Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis", Atherosclerosis, 210, pp.353~361 (2010)
  41. Sharma M, "Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia", Ann Intern Med, 151, pp.622~630 (2009)
  42. ACCORD Study Group, "Effects of combination lipid therapy in type2 diabetes mellitus", N Engl J Med, 362, pp.1563~1574 (2010)
  43. Saha SA, "Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials", Int J Cardiol, 141, pp.157~166 (2010)
  44. Jun M, "Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis", Lancet, 375, pp.1875~1884 (2010)
  45. Gupta A, "Systematic review on evidence of the effectiveness of cholesterol-lowering drugs", Adv Ther, 27, pp.348~364 (2010)
  46. "Guidelines for management of ischaemic stroke and transient ischaemic attack 2008", Cerebrovasc Dis, 25, pp.457~507 (2008)
  47. Ross R, "Atherosclerosis -- an Inflammatory disease", N Engl J Med, 340, pp.115~126 (1999)
  48. Folsom AR, "C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study", Am Heart J, 144, pp.233~238 (2002)
  49. Ridker PM, "Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events", N Engl J Med, 347, pp.1557~1565 (2002)
  50. Cannon CP, "Intensive versus moderate lipid lowering with statins after acute coronary syndromes", N Engl J Med, 350, pp.1495~1504 (2004)
  51. Nissen SE, "Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial", JAMA, 291, pp.1071~1080 (2004)
  52. Nissen SE, "Statin Therapy, LDL cholesterol, C-Reactive protein, and coronary artery disease", N Engl J Med, 352, pp.29~38 (2005)
  53. Ridker PM, "Measurement of C-reactive protein for the targeting of dtatin therapy in the primary prevention of acute coronary events", N Engl J Med, 344, pp.1959~1965 (2001)
  54. Garza CA, "Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review", Mayo Clin Proc, 82, pp.159~165 (2007)
  55. Kaptoge S, "C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis", Lancet, 375, pp.132~140 (2010)
  56. Nambi V, "Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study", Stroke, 40, pp.376~381 (2009)

관련 논문AI추천

Stroke Update 2009: 뇌졸중의 위험인자 및 일차 예방박종무대한뇌졸중학회 · 대한뇌졸중영문학회지2009 · 제11권 제2호Stroke Update: 위험인자 및 일차예방김재국, 이수주대한뇌졸중학회 · 대한뇌졸중영문학회지2012 · 제14권 제1호한국뇌졸중진료지침에서 아스피린의 뇌졸중 일차예방효과에 관한 내용의 부분개정강규식, 구자성, 권순억, 김한영, 나정호, 박종무, 배희준, 오창완, 유경호, 윤병우, 이병철, 조용진, 한상원, 허지회, 홍근식대한신경과학회 · 대한신경과학회지2011 · 제29권 제4호Low-Density Lipoprotein Cholesterol Level, the Lower the Better? Analysis of Korean Patients in the Treat Stroke to Target TrialByung-Chul Lee, Eung-Gyu Kim, Hanim Kwon, Jae-Chan Ryu, Jae-Kwan Cha, Jei Kim, Ji Hoe Heo, Jong S. Kim, Keun-Sik Hong, Kyung Bok Lee, Kyusik Kang, Man Seok Park, Oh Young Bang, Sang Min Sung, Tae-Jin Song, Yong-Won Kim대한뇌졸중학회 · 대한뇌졸중영문학회지2025 · 제27권 제2호뇌졸중 이후의 이상지혈증의 관리송태진, 장윤경대한신경과학회 · 대한신경과학회지2022 · 제40권 제3호2009년 한국 뇌졸중 진료지침에서 이차예방을 위한 항혈소판제의 사용에 관한 내용의 부분 개정권순억, 권형민, 나정호, 배희준, 오창완, 유경호, 윤병우, 이병철, 허지회, 홍근식대한신경과학회 · 대한신경과학회지2010 · 제28권 제2호

이 간행물의 다른 논문 (24건)

비심장성뇌경색의 항혈소판제치료 실패의 예측인자박선아, 이태경, 성기범, 박정호, 김태은, 허덕현, 이동현, 허태훈pp. 170-175초음파검사를 이용한 수근관증후군의 중증도 평가정일영, 박경석, 양혜란, 정경숙, 김남희pp. 176-181혈관내피성장인자유전자 단일뉴클레오티드다형태와 대뇌백질변성 위험성의 연관성분석김남근, 김옥준, 오승헌, 김미화, 안세아, 박소영pp. 182-189허혈뇌졸중과 일과성허혈발작 환자에서 말초동맥질환의 위험인자마효일, 김유경, 도주영, 김예림, 유경호, 박현주, 이병철, 오미선pp. 190-195비류마티스 환축추 불완전탈구에서 발생한 경부척수병김진옥, 이수주, 장상현, 고영채, 윤동주, 김효정, 오건세, 윤수진pp. 196-199
원문 보기